Dibenzoyl-L-tartaric acid monohydrate

Dibenzoyl-L-tartaric acid monohydrate (CAS 62708-56-9), commonly abbreviated as L-DBTA, is a chiral resolving agent derived from L-tartaric acid. It is used primarily in pharmaceutical manufacturing to separate racemic mixtures.

The separation occurs through diastereomeric salt formation, allowing for the isolation of enantiomerically pure compounds. L-DBTA is most extensively used in the resolution of chiral amines, amino acids, and alkaloid-type APIs.

This process is essential where a single enantiomer is required for regulatory approval. In active pharmaceutical ingredient synthesis, it enables the isolation of target enantiomers at pilot and commercial scale.

By utilizing this resolving agent, manufacturers can avoid the high costs and complexity of chiral chromatography. Biotechnology processes also employ it in the production of chiral building blocks for peptide drug candidates.

It is equally effective for small-molecule drug candidates during the development phase. In specialty chemical manufacturing, it also functions as a chiral catalyst precursor in various asymmetric synthesis workflows.

Dibenzoyl-L-tartaric acid monohydrate is supplied as a white to off-white crystalline powder. It is available in pharmaceutical-grade and reagent-grade specifications to meet the purity requirements of API manufacturing.

The material is produced to meet rigorous quality standards for research applications. Packaging is typically offered in laboratory quantities through to multi-kilogram lots for process-scale use in industrial facilities.